Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | HRAS |
Variant | G12D |
Impact List | missense |
Protein Effect | loss of function |
Gene Variant Descriptions | HRAS G12D does not lie within any known functional domains of the Hras protein (UniProt.org). G12D results in decreased Hras GTPase activity, loss of sensitivity to GTPase-activating proteins, thus leads to transformation of cells in culture (PMID: 24224811, PMID: 6092966). |
Associated Drug Resistance | |
Category Variants Paths |
HRAS mutant HRAS act mut HRAS G12D HRAS mutant HRAS G12X HRAS G12D |
Transcript | NM_005343.4 |
gDNA | chr11:g.534288C>T |
cDNA | c.35G>A |
Protein | p.G12D |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001130442 | chr11:g.534288C>T | c.35G>A | p.G12D | RefSeq | GRCh38/hg38 |
NM_005343.3 | chr11:g.534288C>T | c.35G>A | p.G12D | RefSeq | GRCh38/hg38 |
NM_005343 | chr11:g.534288C>T | c.35G>A | p.G12D | RefSeq | GRCh38/hg38 |
NM_005343.4 | chr11:g.534288C>T | c.35G>A | p.G12D | RefSeq | GRCh38/hg38 |
NM_176795.4 | chr11:g.534288C>T | c.35G>A | p.G12D | RefSeq | GRCh38/hg38 |
NM_176795.5 | chr11:g.534288C>T | c.35G>A | p.G12D | RefSeq | GRCh38/hg38 |
NM_001130442.2 | chr11:g.534288C>T | c.35G>A | p.G12D | RefSeq | GRCh38/hg38 |
NM_176795 | chr11:g.534288C>T | c.35G>A | p.G12D | RefSeq | GRCh38/hg38 |
NM_001130442.3 | chr11:g.534288C>T | c.35G>A | p.G12D | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05638698 | Phase II | Balstilimab + QS21 + TG01 QS21 + TG01 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA) | Active, not recruiting | USA | 0 |
NCT03745326 | Phase Ib/II | Aldesleukin + anti-KRAS G12D mTCR cells + Cyclophosphamide + Fludarabine | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | Recruiting | USA | 0 |